GLP1 Protocol
stacked_bar_chartBuying guide

Best Selank Source

Three criteria stated first, weighted, and only then applied to five categories of seller. The order matters more than the result.

Best selank source is a question that can only be answered honestly if the scoring is published before the winner is, so the three criteria come first and the ranking follows them.

Two of the three can be checked in a browser tonight. The third only reveals itself once an order exists. Everything here is research material for laboratory use and is not for human consumption, and the links to the top entry are affiliate links.

Where the order actually gets placed

Ascension Peptides, Selank

US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.

CodePEPTIDEDECK50% off
Selank · 10 mg$47.50$23.75Get the 10 mg →

The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.

How this best selank source ranking is scored

Testing scope, weighted heaviest. Not whether a certificate exists, but what it covers and how easily you can reach it. A full result names a laboratory and a lot, confirms purity by HPLC, confirms identity against the expected monoisotopic mass of 751.43 Da for the seven-residue sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, measures the quantity actually in the vial, and, for anything that might be injected, reports bacterial endotoxin.

This criterion carries the most weight because it is the one the regulator pointed at. FDA writes, on a compounding page current as of 22 April 2026, that compounded drugs containing selank acetate "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities". Aggregation and impurities are a purity and identity question. Immunogenicity on an injected route is an endotoxin question. A source that answers both has answered the concern on the record; a source that answers neither has answered nothing.

Time to hand, meaning where the vial physically sits when you pay. A seller with domestic inventory states a dispatch cutoff as a clock time. A seller without it states a handling window in business days. This criterion quietly carries recourse as well, because a supplier inside your jurisdiction is one your consumer rules reach and one a carrier claim can be filed against.

Price, meaning what the per-milligram figure actually covers. A number is comparable only when you know the label quantity, the discount mechanics and what lands on the total after shipping, duty and handling.

Two notes that apply to every entry. Selank has no FDA approval for any indication, and it is on no current FDA category list: it was nominated for the 503A bulks list and the nomination was withdrawn, which is different from being refused and very different from being banned. Its Russian anxiolytic registration is a fact about Russian regulation and not evidence by Western regulatory standards. No source on this page changes either of those.

The ranking

1. Ascension Peptides

First on scope, which is where the weighting sits, and the margin is larger than it first appears because half the evidence is easy to miss.

The linked certificate, for lot 29-01260229, comes from MZ Biolabs in Tucson with an analysis date of 2026-02-07. It reports 99.32% purity by HPLC-UV and confirms identity by mass spectrometry at 751.47 Da against the 751.43 Da expected, and it states an assayed 12.29 mg in a vial labelled 10 mg. It contains no endotoxin, LAL, pyrogen or sterility test, and a reader who stops there concludes this source scores poorly on the heaviest criterion.

The product page carries a second certificate, from a different laboratory, shown as images under a heading naming Kovera Labs and batch 29-05260628. That report states 99.371% purity, net content of 11.86 mg against the 10 mg label, identity by LC-MS, a kinetic chromogenic LAL endotoxin assay to USP Chapter 85 reporting under 0.20 EU/mL against a 0.5 EU/mL limit, a microbial sterility screen returning no growth, and heavy metals screening for arsenic, lead and mercury.

Two independent laboratories, two batches, and between them the whole panel. That is an unusually complete answer for this market. The one mark against it is presentation: the narrower document is the clickable one, and the fuller document is the one most buyers never open. Both assayed quantities are lot-specific measurements rather than standing promises, so neither should be treated as a specification for the next vial.

On time, same-day dispatch is stated for orders placed before 2pm CST, which only domestic inventory supports. On price, the 10 mg vial is $47.50, down from $60.00, and $23.75 with the code PEPTIDEDECK, which is $2.38 per milligram on the label weight. Buying 3, 5 or 10 takes 3%, 5% or 10% off list, and nothing published says the code stacks with those tiers. Free shipping starts at $250.

2. US research suppliers publishing one certificate per lot

The broad, legitimate middle of this market, and a perfectly reasonable selank vendor for many buyers.

They score well on time and price and lose to the top entry on scope alone. One laboratory means the relationship between tester and seller is invisible to you and there is no second reading to compare against, and in practice a single certificate here is usually a purity and identity document with no endotoxin work attached. That is the same shape as the February report above, without the second document sitting behind it.

3. Consumer nootropic retailers selling nasal sprays

Third, which surprises people, and the reasoning is worth stating because it exposes what the criteria are actually measuring.

On scope they are the weakest entrants on this page. A pre-mixed solution in a multi-use bottle raises sterility and preservative questions rather than settling them, and these listings usually publish no batch testing whatsoever, sometimes not even a checkable peptide quantity per bottle. On the other two criteria they do well: the parcel ships domestically in days, and there is a real consumer business behind it that a card issuer and a regulator can both reach.

They finish above the two entries below them because failing one criterion badly is a better position than failing all three moderately.

4. US-facing storefronts that ship from a foreign warehouse

Indistinguishable from entry two on a product page, and different the moment an order exists.

The tell is in the wording. A handling window in business days rather than a dispatch cutoff, and shipping terms that mention customs at all. Scope is usually a single generic document that is not tied to a lot, time is unpredictable because a border sits inside it, and the recourse implied by the domestic-looking storefront does not exist.

5. Overseas bulk sellers priced by the gram

Cheapest on the headline and last on the weighting.

Scope fails structurally rather than accidentally: a product-level certificate republished for every shipment cannot describe the material that reached you, which makes the heaviest criterion unanswerable no matter how good the underlying powder is. Time runs to weeks, with clearance rather than transit taking most of it. The price advantage narrows once international shipping, VAT and carrier handling charges are added, and disappears entirely on any parcel that is stopped.

Running the scoring yourself

The ranking above is worth exactly as much as your ability to reproduce it, so here is the whole method in a form you can apply to any seller in ten minutes.

Open the product page and count the certificates rather than clicking the first one. Sellers in this market frequently display more than one and link only some of them, which means the number of documents on the page and the number of links on the page are different figures. For each certificate you find, note four things: the laboratory name, the lot or batch number, the analysis date, and the list of tests actually run. A document missing any of the first three cannot be tied to a vial and scores nothing regardless of how good its numbers look.

Then check the tests against the compound. Purity should be reported by HPLC with a peak list or trace, not asserted in body copy. Identity should be confirmed against the expected mass for a seven-residue peptide rather than a generic pass mark. Endotoxin, where it appears, should name a method and a limit, and a result reported against a stated limit is worth far more than the word tested.

Finally, read the shipping page for a clock time and the checkout for a payment method that can be reversed. Those two lines decide the second and third criteria between them, and neither requires you to place an order to find out.

What is deliberately not ranked

Group buys, forum splits and social resellers are not sources for the purposes of this list. Decanted or relabelled material has no chain back to a certificate, so it cannot be scored on the criterion that carries the most weight, and no screenshot repairs that.

Compounding pharmacies are not ranked either, and here the reason is specific to Selank rather than a general view of pharmacies. A 503A pharmacy compounding from a bulk substance needs that substance to have an applicable USP monograph, to be a component of an approved drug, or to appear on the bulks list in 21 CFR 216.23. Selank meets none of those conditions. On FDA's compounding safety page it sits in the table of substances nominated but withdrawn, alongside BPC-157, MOTs-C, Semax and TB-500, meaning the nomination was pulled before any determination was reached. The channel is not banned and it is not open; it simply cannot supply anyone today, which is why anyone searching for the best place to buy selank is choosing among research suppliers by default rather than by preference.

Common questions

Common Concerns

Why is testing scope weighted above price?expand_more
Because price is knowable from the listing and scope is not, and because the thing scope measures is the thing FDA actually raised. The agency's concern is immunogenicity risk from aggregation and peptide-related impurities, which is answered by purity, identity and endotoxin data rather than by a per-mg figure. A cheaper vial with no endotoxin result anywhere behind it has not been shown to be worse, and it has not been shown to be anything. Price separates sources that have already cleared the first criterion.
Why are there no invented vendor names below the top entry?expand_more
Because we can verify what one supplier publishes and cannot verify a second and third to the same standard. Naming five companies and attaching plausible prices to four of them is the standard failure of roundups in this market, and it produces a page that is confidently wrong within months. Categories describe what the scoring can actually reach, and they stay true as individual storefronts appear and disappear.
Does a spray retailer really outrank an overseas bulk seller?expand_more
On these criteria, yes, and it is worth seeing why. A domestic consumer retailer loses badly on scope, usually publishing no batch testing at all, and it wins on the other two: the parcel arrives in days without a border in the way, and there is a business inside your jurisdiction to complain to. An overseas bulk seller loses on scope for a different reason, publishing a document that cannot be tied to your material, and then loses on time and recourse as well. Losing one criterion beats losing all three.
What would move the top entry down this list?expand_more
Two things. Publishing a new lot without a certificate covering it would do it immediately, because batch-specific testing that is not kept current reverts to being a marketing asset. Attaching human dosing guidance to the listing would do it too, since that contradicts the research-use basis of the sale and signals a change in how the seller thinks about liability. Neither has happened, and both are checkable by anyone at any time.
Does a compounding pharmacy belong anywhere on this list?expand_more
No, and the reason is regulatory rather than a judgement about pharmacies. Selank is not on the 503A bulks list in 21 CFR 216.23, is not a component of an approved drug, and has no applicable USP monograph, so there is no lawful route for a 503A pharmacy to compound it from bulk. Its nomination for that list was withdrawn rather than refused, which is a distinction most pages get wrong. A pharmacy that offers to supply it anyway has told you something about itself rather than about Selank.

Keep exploring

The same three-criterion method applied to a peptide with two laboratories signing every lot is the BPC-157 ranking scored on paper, time and price, which is the closest structural comparison on this site. Where a genuine clinic channel exists and has to be scored against shipping, the NAD+ ranking judged before you pay shows what changes. And the MOTS-c ranking built around speed to your door is the version where time carries the heaviest weight instead of scope.

Sources